PF-07321332

‌Paxlovid (CAS 2628280-40-8)‌
🌟 ‌ChemicalBook Product Introduction‌

📌 ‌Product Overview‌

‌Paxlovid‌ is an ‌FDA-approved antiviral medication‌ developed by Pfizer for treating ‌mild-to-moderate COVID-19‌ in adults with high-risk factors, such as obesity, diabetes, or cardiovascular diseases. Its active ingredients, ‌Nirmatrelvir (PF-07321332)‌ and ‌Ritonavir‌, work synergistically to inhibit the SARS-CoV-2 3CL protease, blocking viral replication. The compound is supplied as a white crystalline powder with a molecular formula of ‌C23H32F3N5O4‌ and a purity of ‌≥99% (HPLC verified)‌.

‌Google Keywords‌: Paxlovid CAS 2628280-40-8, Nirmatrelvir Supplier, COVID-19 Antiviral API, High-Purity Ritonavir

✅ ‌Key Advantages‌

       🔹 ‌High Purity & Stability‌

• ‌≥99% purity‌ (HPLC/UV verified) | Stable storage at ‌2-8°C‌.
  🔹 ‌Dual-Action Formula‌

• Combines ‌Nirmatrelvir‌ (protease inhibitor) and ‌Ritonavir‌ (bioavailability enhancer) for enhanced efficacy.
  🔹 ‌Global Compliance‌

• Produced in ‌GMP-certified facilities‌ | Meets ‌EP/USP/CP‌ standards.

🏥 ‌Application Fields‌

• ‌COVID-19 Treatment‌: Primary use for high-risk adults within 5 days of symptom onset.

• ‌Clinical Research‌: Development of antiviral therapies and resistance studies.

• ‌Combination Therapies‌: Potential synergy with immunomodulators or other antivirals.

📜 ‌Quality Certifications‌

• ‌Testing Methods‌: HPLC, NMR, MS, and microbial limit testing.

• ‌Certifications‌: ‌ISO 9001‌, ‌GMP‌, and ‌FDA-aligned protocols‌.

📊 ‌Market Trends‌

The global demand for ‌COVID-19 therapeutics‌ remains strong, particularly in Asia-Pacific regions, driven by emerging variants and post-pandemic preparedness. Paxlovid continues to be a critical tool in managing high-risk cases.